In cases of resistance to imatinib or dasatinib, the likelihood of maintaining response, disease-free survival and overall survival from 12 months about are 27%, 32
In cases of resistance to imatinib or dasatinib, the likelihood of maintaining response, disease-free survival and overall survival from 12…